The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- Author
- ROSENSTOCK, Julio1 ; BALAS, Bogdan2 ; CHARBONNEL, Bernard3 ; BOLLI, Geremia B4 ; BOLDRIN, Mark5 ; RATNER, Robert6 ; BALENA, Raffaella2
[1] Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, United States
[2] F. Hoffmann-La Roche Ltd., Basel, Switzerland
[3] Department of Internal Medicine, Endocrinology, and Diabetes, University of Nantes, Nantes, France
[4] Department of Internal Medicine, University of Perugia, Perugia, Italy
[5] Roche, Nutley, New Jersey, United States
[6] MedStar Health Research Institute, Hyattsville, Maryland, United States
THE T-EMERGE 2 STUDY GROUP - Source
Diabetes care. 2013, Vol 36, Num 3, pp 498-504, 7 p ; ref : 14 ref
- CODEN
- DICAD2
- ISSN
- 0149-5992
- Scientific domain
- Endocrinology; Nutrition, obesity, metabolic disorders
- Publisher
- American Diabetes Association, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agoniste Diabète de type 2 Endocrinologie Essai clinique Etude comparative Exénatide Hebdomadaire Homme Hypoglycémiant Maladie métabolique Nutrition Quotidien Récepteur GLP-1 Analogue Endocrinopathie Hormone gastrointestinale Peptide GLP1
- Keyword (en)
- Agonist Type 2 diabetes Endocrinology Clinical trial Comparative study Exenatide Weekly Human Hypoglycemic agent Metabolic diseases Nutrition Daily Analog Endocrinopathy Gastrointestinal hormone Glucagon like peptide 1
- Keyword (es)
- Agonista Diabetes de tipo 2 Endocrinología Ensayo clínico Estudio comparativo Exenatida Semanal Hombre Hipoglicemiante Metabolismo patología Nutrición Cotidiano Análogo Endocrinopatía Hormona gastrointestinal Péptido GLP1
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B30 Public health. Hygiene-occupational medicine / 002B30A Public health. Hygiene / 002B30A11 Miscellaneous
- Discipline
- Endocrinopathies Metabolic diseases Public health. Hygiene-occupational medicine
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27062596
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2337/dc12-0709 
https://dx.doi.org/10.2337/dc12-0709
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc12-0709\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"498\";s:8:\"\u0000*\u0000epage\";s:3:\"504\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ROSENSTOCK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Julio\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"BALAS, Bogdan\";i:1;s:19:\"CHARBONNEL, Bernard\";i:2;s:16:\"BOLLI, Geremia B\";i:3;s:13:\"BOLDRIN, Mark\";i:4;s:14:\"RATNER, Robert\";i:5;s:17:\"BALENA, Raffaella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc12-0709\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"498\";s:8:\"\u0000*\u0000epage\";s:3:\"504\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ROSENSTOCK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Julio\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"BALAS, Bogdan\";i:1;s:19:\"CHARBONNEL, Bernard\";i:2;s:16:\"BOLLI, Geremia B\";i:3;s:13:\"BOLDRIN, Mark\";i:4;s:14:\"RATNER, Robert\";i:5;s:17:\"BALENA, Raffaella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc12-0709\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc12-0709\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"498\";s:8:\"\u0000*\u0000epage\";s:3:\"504\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ROSENSTOCK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Julio\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"BALAS, Bogdan\";i:1;s:19:\"CHARBONNEL, Bernard\";i:2;s:16:\"BOLLI, Geremia B\";i:3;s:13:\"BOLDRIN, Mark\";i:4;s:14:\"RATNER, Robert\";i:5;s:17:\"BALENA, Raffaella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc12-0709\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"498\";s:8:\"\u0000*\u0000epage\";s:3:\"504\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ROSENSTOCK\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Julio\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:13:\"BALAS, Bogdan\";i:1;s:19:\"CHARBONNEL, Bernard\";i:2;s:16:\"BOLLI, Geremia B\";i:3;s:13:\"BOLDRIN, Mark\";i:4;s:14:\"RATNER, Robert\";i:5;s:17:\"BALENA, Raffaella\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:129:\"The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
